CN1041520C - 喹啉或喹唑啉衍生物,它们的制法和用途 - Google Patents

喹啉或喹唑啉衍生物,它们的制法和用途 Download PDF

Info

Publication number
CN1041520C
CN1041520C CN94101137A CN94101137A CN1041520C CN 1041520 C CN1041520 C CN 1041520C CN 94101137 A CN94101137 A CN 94101137A CN 94101137 A CN94101137 A CN 94101137A CN 1041520 C CN1041520 C CN 1041520C
Authority
CN
China
Prior art keywords
compound
ring
group
salt
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94101137A
Other languages
English (en)
Chinese (zh)
Other versions
CN1105363A (zh
Inventor
左右田隆
牧野治彦
马场厚生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CN1105363A publication Critical patent/CN1105363A/zh
Application granted granted Critical
Publication of CN1041520C publication Critical patent/CN1041520C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
CN94101137A 1993-01-28 1994-01-28 喹啉或喹唑啉衍生物,它们的制法和用途 Expired - Fee Related CN1041520C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP1262893 1993-01-28
JP012628/93 1993-01-28
JP206128/93 1993-08-20
JP20612893 1993-08-20

Publications (2)

Publication Number Publication Date
CN1105363A CN1105363A (zh) 1995-07-19
CN1041520C true CN1041520C (zh) 1999-01-06

Family

ID=26348258

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94101137A Expired - Fee Related CN1041520C (zh) 1993-01-28 1994-01-28 喹啉或喹唑啉衍生物,它们的制法和用途

Country Status (15)

Country Link
US (3) US5436247A (cg-RX-API-DMAC10.html)
EP (1) EP0608870B1 (cg-RX-API-DMAC10.html)
KR (1) KR100224135B1 (cg-RX-API-DMAC10.html)
CN (1) CN1041520C (cg-RX-API-DMAC10.html)
AT (1) ATE205199T1 (cg-RX-API-DMAC10.html)
AU (1) AU673213B2 (cg-RX-API-DMAC10.html)
CA (1) CA2114300C (cg-RX-API-DMAC10.html)
DE (1) DE69428142T2 (cg-RX-API-DMAC10.html)
FI (1) FI940414L (cg-RX-API-DMAC10.html)
HU (1) HU217907B (cg-RX-API-DMAC10.html)
NO (2) NO940245D0 (cg-RX-API-DMAC10.html)
NZ (1) NZ250761A (cg-RX-API-DMAC10.html)
RU (1) RU2132330C1 (cg-RX-API-DMAC10.html)
SG (1) SG50546A1 (cg-RX-API-DMAC10.html)
TW (1) TW256832B (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW232013B (cg-RX-API-DMAC10.html) * 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
KR100224135B1 (ko) * 1993-01-28 1999-10-15 다께다 구니오 퀴놀린 또는 퀴나졸린 유도체, 그 제조 및 용도
EP0634169B1 (en) * 1993-06-29 2000-01-05 Takeda Chemical Industries, Ltd. Quinoline or quinazoline derivatives and their use in the manufacture of a medicament for the treatment of osteoporosis
AU1860995A (en) * 1994-03-08 1995-09-25 Takeda Chemical Industries Ltd. Quinoline or quinazoline derivatives as anti-inflammatory agents, in particular for treating arthritis
US5641788A (en) * 1994-06-07 1997-06-24 Takeda Chemical Industries, Ltd. Quinoline derivatives and pharmaceutical composition containing them
EP0766681A1 (en) * 1994-06-24 1997-04-09 Takeda Chemical Industries, Ltd. Processes for production of quinoline or quinazoline derivatives and intermediates therefor
US5523312A (en) * 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
AU715358B2 (en) * 1995-04-28 2000-01-20 Takeda Chemical Industries Ltd. Therapeutic composition for arthritis
DE19610882A1 (de) * 1996-03-20 1997-09-25 Dresden Arzneimittel Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BR9809501A (pt) * 1997-05-28 2000-06-20 Rhone Poulenc Rorer Pharma Composto, composição farmacêutica, e, processos para inibir a atividade da tirosina quinase pdgf, para inibir a atividade da tirosina quinase lck, para inibir a proliferação celular, diferenciação ou liberação de mediador em um paciente, para tratar uma patologia ligada a um distúrbio hiperproliferativo, para tratar a restenose, e, para tratar inflamação em um paciente
DE19728835C1 (de) * 1997-07-05 1998-09-10 Ruetgers Vft Ag Verfahren zur Reinigung von Chinaldin
RU2263674C2 (ru) * 2000-01-17 2005-11-10 Тейдзин Лимитед Бензимидазольное производное, ингибитор человеческой химазы, терапевтический агент и фармацевтическая композиция на его основе
EP1354603A1 (en) * 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
RU2183116C1 (ru) * 2001-07-10 2002-06-10 Жаров Олег Владимирович Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием
US6861525B2 (en) * 2002-07-15 2005-03-01 Scinopharm Taiwan, Ltd. Process for the preparation imidazo[1,2-A]pyridine-3-acetamides
AU2003277572A1 (en) * 2002-11-06 2004-06-07 Nissan Chemical Industries, Ltd. Process for producing quinolinecarbaldehyde
ES2290743T3 (es) * 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
US7937406B2 (en) * 2003-09-11 2011-05-03 Oracle America, Inc. Mechanism for automatically establishing a resource grid
MX2007005112A (es) * 2004-11-01 2007-06-26 Hoffmann La Roche Quinolinas como intensificadores alostericos de receptores de acido gamma-aminobutirico-b.
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
EP2001547A2 (en) * 2006-03-21 2008-12-17 ALZA Corporation Hydratable polymeric ester matrix for drug electrotransport
US20100331306A1 (en) 2009-06-25 2010-12-30 Amgen Inc. Heterocyclic compounds and their uses
WO2012068343A1 (en) * 2010-11-17 2012-05-24 Amgen Inc. Quinoline derivatives as pik3 inhibitors
WO2014029723A1 (en) * 2012-08-24 2014-02-27 F. Hoffmann-La Roche Ag New bicyclicpyridine derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563455A (en) * 1983-03-22 1986-01-07 Fujisawa Pharmaceutical Co., Ltd. Antiulcer fused imidazole compounds
US5151421A (en) * 1988-11-29 1992-09-29 Janssen Pharmaceutica N.V. (1h-azol-1-ylmethyl) substituted quinoxaline derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438267A (en) * 1980-11-11 1984-03-20 Daluge Susan M Monoheteroring compounds and their use
US5084462A (en) * 1988-04-26 1992-01-28 The Du Pont Merck Pharmaceutical Company 4-quinoline carboxylic acid derivatives useful as immunosuppressive agents
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
TW232013B (cg-RX-API-DMAC10.html) * 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
KR100224135B1 (ko) * 1993-01-28 1999-10-15 다께다 구니오 퀴놀린 또는 퀴나졸린 유도체, 그 제조 및 용도
EP0766681A1 (en) * 1994-06-24 1997-04-09 Takeda Chemical Industries, Ltd. Processes for production of quinoline or quinazoline derivatives and intermediates therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563455A (en) * 1983-03-22 1986-01-07 Fujisawa Pharmaceutical Co., Ltd. Antiulcer fused imidazole compounds
US5151421A (en) * 1988-11-29 1992-09-29 Janssen Pharmaceutica N.V. (1h-azol-1-ylmethyl) substituted quinoxaline derivatives

Also Published As

Publication number Publication date
ATE205199T1 (de) 2001-09-15
CA2114300C (en) 2000-10-17
US5932592A (en) 1999-08-03
FI940414A7 (fi) 1994-07-29
NO306992B1 (no) 2000-01-24
EP0608870B1 (en) 2001-09-05
US5770602A (en) 1998-06-23
TW256832B (cg-RX-API-DMAC10.html) 1995-09-11
HU9400250D0 (en) 1994-05-30
CA2114300A1 (en) 1994-07-29
KR100224135B1 (ko) 1999-10-15
AU673213B2 (en) 1996-10-31
FI940414A0 (fi) 1994-01-27
EP0608870A1 (en) 1994-08-03
DE69428142T2 (de) 2002-07-04
HU217907B (hu) 2000-05-28
NO940245D0 (no) 1994-01-24
AU5474294A (en) 1994-08-04
FI940414L (fi) 1994-07-29
SG50546A1 (en) 1998-07-20
NZ250761A (en) 1995-03-28
US5436247A (en) 1995-07-25
DE69428142D1 (de) 2001-10-11
HUT70194A (en) 1995-09-28
NO940245L (no) 1994-07-29
RU2132330C1 (ru) 1999-06-27
CN1105363A (zh) 1995-07-19
KR940018381A (ko) 1994-08-16

Similar Documents

Publication Publication Date Title
CN1041520C (zh) 喹啉或喹唑啉衍生物,它们的制法和用途
CN1022566C (zh) 制备新的取代的1-哌啶亚烷基-吡啶并嘧啶酮或噻唑并嘧啶酮的方法
TWI813611B (zh) 作為parp14抑制劑之喹唑啉酮
JP7085566B2 (ja) アポトーシス誘発剤
JP5853035B2 (ja) β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な３，４−ジヒドロ−ピロロ［１，２−ａ］ピラジン−１−イルアミン誘導体
CN1060472C (zh) 三环取代异羟肟酸衍生物其制备方法、含有它们的药物及其用途
SG185652A1 (en) 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace)
CN1429200A (zh) 邻氨基苯甲酸酰胺及其作为药物的应用
RU2649976C2 (ru) Способ получения бензоксазепиновых соединений
KR101698283B1 (ko) 티에노피리미딘 화합물의 제조 방법
CN1502608A (zh) 具有抑制血管生成活性的六员氨基酰胺类衍生物
CN1195741C (zh) 嘧啶酮化合物,包含该化合物的药物组合物以及制备该化合物的方法
CN1280292C (zh) 用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物
CN1046505C (zh) 1－苄基－3－羟甲基－吲唑与脂族2－羟基酸的醚的制法
CN111315734B (zh) 作为食欲素受体拮抗剂的经取代的2-氮杂双环[3.1.1]庚烷和2-氮杂双环[3.2.1]辛烷衍生物
CN1071754C (zh) 嘧啶基吡唑衍生物
CN1269811C (zh) 具有sst1拮抗活性的哌嗪衍生物
CN1094406A (zh) 用于治疗人体识别障碍的3，3′-二取代的-1，3-二氢-2H-吡咯[2，3-b]杂环-2-酮
CN1009826B (zh) 制备喹啉基化合物的方法
CN86103227A (zh) 制备2-吡咯烷酮衍生物的方法
EP3424927B1 (en) Efficient process for the preparation of sitagliptin through a very effective preparation of the intermediate 2,4,5-trifluorophenylacetic acid
CN1194982A (zh) 磺酰氨取代的苯并二氢吡喃、其制备方法、它们作为药物或诊断剂的用途和含有它们的药物
TW200817322A (en) Compounds having activity at the GlyT1 transporter
CN1198735A (zh) 苯磺酰胺衍生物以及它们的制备和在医领域中的应用
CN1606557A (zh) 经氘代的吡唑嘧啶酮以及包含该化合物的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee